JP2024520359A - Alk2キナーゼのイミダゾール含有阻害剤 - Google Patents

Alk2キナーゼのイミダゾール含有阻害剤 Download PDF

Info

Publication number
JP2024520359A
JP2024520359A JP2023571902A JP2023571902A JP2024520359A JP 2024520359 A JP2024520359 A JP 2024520359A JP 2023571902 A JP2023571902 A JP 2023571902A JP 2023571902 A JP2023571902 A JP 2023571902A JP 2024520359 A JP2024520359 A JP 2024520359A
Authority
JP
Japan
Prior art keywords
compound
alkyl
mmol
cycloalkyl
trimethoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520359A5 (cg-RX-API-DMAC7.html
Inventor
エル コティアン,プラヴィン
エス バブ,ヤーラガダ
ヂャン,ウェイハァ
エルヴィー,ウェイ
ルゥ,ポン-チォン
イー スポルディング,アンドリュー
ラマン,クリシュナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of JP2024520359A publication Critical patent/JP2024520359A/ja
Publication of JP2024520359A5 publication Critical patent/JP2024520359A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023571902A 2021-05-25 2022-05-24 Alk2キナーゼのイミダゾール含有阻害剤 Pending JP2024520359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192822P 2021-05-25 2021-05-25
US63/192,822 2021-05-25
PCT/US2022/030690 WO2022251188A2 (en) 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase

Publications (2)

Publication Number Publication Date
JP2024520359A true JP2024520359A (ja) 2024-05-24
JP2024520359A5 JP2024520359A5 (cg-RX-API-DMAC7.html) 2025-05-29

Family

ID=84230377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571902A Pending JP2024520359A (ja) 2021-05-25 2022-05-24 Alk2キナーゼのイミダゾール含有阻害剤

Country Status (23)

Country Link
US (1) US20240270750A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346806A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520359A (cg-RX-API-DMAC7.html)
KR (1) KR20240013145A (cg-RX-API-DMAC7.html)
CN (1) CN117529315A (cg-RX-API-DMAC7.html)
AR (1) AR125963A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022283258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024537A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219966A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003503A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230597A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000254A (cg-RX-API-DMAC7.html)
EC (1) ECSP23096182A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416425A (cg-RX-API-DMAC7.html)
IL (1) IL308513A (cg-RX-API-DMAC7.html)
JO (1) JOP20230303A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013742A (cg-RX-API-DMAC7.html)
PE (1) PE20250022A1 (cg-RX-API-DMAC7.html)
PY (1) PY2240952A (cg-RX-API-DMAC7.html)
TW (1) TW202313625A (cg-RX-API-DMAC7.html)
UY (1) UY39788A (cg-RX-API-DMAC7.html)
WO (1) WO2022251188A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501914A (ja) * 2000-06-28 2004-01-22 アストラゼネカ アクチボラグ 置換キナゾリン誘導体及び、阻害剤としてのそれらの使用
JP2013032343A (ja) * 2011-06-29 2013-02-14 Otsuka Pharmaceut Co Ltd 治療用化合物、及び関連する使用の方法
WO2018121400A1 (zh) * 2016-12-27 2018-07-05 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
JP2020523351A (ja) * 2017-06-15 2020-08-06 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. Alk2キナーゼのイミダゾール含有阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501914A (ja) * 2000-06-28 2004-01-22 アストラゼネカ アクチボラグ 置換キナゾリン誘導体及び、阻害剤としてのそれらの使用
JP2013032343A (ja) * 2011-06-29 2013-02-14 Otsuka Pharmaceut Co Ltd 治療用化合物、及び関連する使用の方法
WO2018121400A1 (zh) * 2016-12-27 2018-07-05 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
JP2020523351A (ja) * 2017-06-15 2020-08-06 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. Alk2キナーゼのイミダゾール含有阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY, vol. RN 903468-12-2, JPN7026000670, August 2006 (2006-08-01), ISSN: 0005798767 *

Also Published As

Publication number Publication date
BR112023024537A2 (pt) 2024-02-06
UY39788A (es) 2023-01-31
IL308513A (en) 2024-01-01
PY2240952A (es) 2022-12-26
EP4346806A2 (en) 2024-04-10
DOP2023000254A (es) 2023-12-29
US20240270750A1 (en) 2024-08-15
CA3219966A1 (en) 2022-12-01
AR125963A1 (es) 2023-08-30
ECSP23096182A (es) 2024-01-31
JOP20230303A1 (ar) 2023-11-23
MX2023013742A (es) 2023-11-28
WO2022251188A3 (en) 2023-01-05
AU2022283258A1 (en) 2024-01-04
KR20240013145A (ko) 2024-01-30
PE20250022A1 (es) 2025-01-07
CR20230597A (es) 2024-02-20
CL2023003503A1 (es) 2024-05-03
WO2022251188A8 (en) 2024-01-04
WO2022251188A2 (en) 2022-12-01
CO2023017975A2 (es) 2024-01-15
EP4346806A4 (en) 2025-07-23
CN117529315A (zh) 2024-02-06
TW202313625A (zh) 2023-04-01
GEAP202416425A (en) 2024-02-12

Similar Documents

Publication Publication Date Title
WO2022174031A1 (en) Cdk inhibitors and methods of use thereof
JP6204568B2 (ja) タンパク質キナーゼ阻害剤としての縮合複素環化合物
CA2526578C (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
RU2318826C2 (ru) Производные 4-амино-6-фенилпирроло[2,3] пиримидина, обладающие ингибирующим действием в отношении действия тирозинкиназы, их применение и способы получения (варианты)
EP4573089A2 (en) Kras inhibitors
AU2011305568B2 (en) Imidazotriazinone compounds
JP2024517693A (ja) 2-アミノベンゾチアゾール化合物及びその使用方法
AU2016348620B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2018206111B2 (en) Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof
EP2802586A1 (en) Substituted imidazopyrazines as akt kinase inhibitors
JP2024522588A (ja) 抗がん化合物
EP4436957A1 (en) Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2022096361A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
TW202313625A (zh) 含有咪唑之alk2激酶抑制劑
EA052309B1 (ru) Имидазолсодержащие ингибиторы alk2-киназы
OA21894A (en) Imidazole-Containing Inhibitors Of ALK2 Kinase.
US20150306102A1 (en) Substituted pyrazolopyrimidines as akt kinase inhibitors
CN117136052A (zh) Cdk抑制剂和其使用方法
EA051777B1 (ru) Пирролопиримидинамины в качестве ингибиторов комплемента

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219